## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.8% in upper entry zone (4.0-10.0%), top 4% cross-sectional ranking. Short-term MRS_5 (7.0%) confirms momentum alignment. Strong momentum (+6.8% 5-day acceleration). Outperforming sector by 10.1%. Caution: overbought RSI (75).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($37.50)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Omnicell (Nasdaq: OMCL) to host ASHP Midyear innovation update, investor Q&A**
- Source: Stock Titan | 20251203T110938 | Neutral | Relevance: 100%
- Omnicell, Inc. (Nasdaq: OMCL) announced it will host an Innovation Update and Investor Q&A Session at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas on Monday, December 8, 2025. The Innovation Update will be in-person only, while the Q&A session will be available in person and via webcast. Key Omnicell executives, including Chairman and CEO Randall Lipps, COO Nnamdi Njoku, and CFO Baird Radford, will be present.

**2. Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show**
- Source: Business Wire | 20251202T043223 | Somewhat-Bullish | Relevance: 100%
- Omnicell, Inc. (Nasdaq: OMCL) will host an Innovation Update and Investor Q&A Session during the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas on Monday, December 8, 2025. The Innovation Update will be in-person only, while the Q&A session will be available in-person and via webcast. Key Omnicell executives, including Chairman Randall Lipps, COO Nnamdi Njoku, and CFO Baird Radford, will speak at the event.

**3. What Omnicell (OMCL)'s Upward Earnings Estimate Revisions Mean For Shareholders**
- Source: Sahm | 20251201T043223 | Bullish | Relevance: 100%
- Analysts have become more optimistic about Omnicell (OMCL) due to upward revisions in earnings estimates and a strong Zacks rating, reflecting improving business prospects. This enhanced confidence is driven by the company's raised full-year revenue guidance, indicating traction in automation technologies and a shift toward recurring, cloud-based revenues. Omnicell's investment narrative projects $1.3 billion revenue and $30.4 million earnings by 2028, with a fair value of $47.33, presenting a 29% upside.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 10 ($2.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Elevated short interest (8.9%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +6.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 22.0x stretched relative to 8% growth. Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 8.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 22.0 |
| Current P/E | 23.7 |
| YoY Growth | 7.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 3.0% to 9.8% (+6.8% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 95th percentile. MRS_5 at 7.0% confirms short-term momentum alignment. AM_20 at 11.9% shows strong absolute momentum above own 20MA. Outperforming sector by 10.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 75, risk of mean reversion. OFD pattern: +MLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.84% (CS: 96) | Strong |
| RSI_14 | 75.2 | Overbought |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.119x | Above |
| vs SMA50 | 1.228x | Above |
| vs SMA200 | 1.271x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $40.48
- **Stop Loss:** $37.50 (7.4% risk)
- **Target:** $44.95 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 318
- **Position Value:** $12,872.64
- **Portfolio %:** 12.87%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*